

Summary of November 2016 Changes to 902 KAR 2:020. Reportable disease surveillance

New Reporting Requirements:

- Section 5(17) Varicella
- Section 6
 - (1)(i) Zika virus disease or infection or the birth of a child to a mother who was Zika-positive or Zika-inconclusive during any stage of pregnancy or during the periconceptional period
 - (4) Carbon monoxide poisoning
 - (20) Leptospirosis
- Section 9
 - (g) Cephalosporin-resistant *Klebsiella*, which includes *Klebsiella oxytoca*, *Klebsiella pneumonia*, or a *Klebsiella* species testing non-susceptible (resistant or intermediate) to ceftazidime, cefotaxime, ceftriaxone, or cefepime;

Deleted Previous Reporting Requirements:

- Section 6
 - Rabies post exposure prophylaxis
 - Varicella-associated mortality [reporting of varicella-associated mortality is now included in new reporting requirements for varicella]

Modifications to Previous Reporting Requirements (with Descriptions of Changes:

- Section 4(15)(c) EPID 394, Kentucky Reportable Disease Form, Hepatitis Infection in Pregnant Women or Child (aged five (5) years or less) [the title of the form was changed]
- Section 6
 - (12) Hantavirus infection, non-Hantavirus pulmonary syndrome [reporting previously required for “Hantavirus infections”]
 - (13) Hantavirus pulmonary syndrome (HPS) [reporting previously required for “Hantavirus infections”]
 - (17) Hepatitis B infection in an infant or a child aged five (5) years or less [added (5) after five]
 - (19) Influenza-associated mortality [reporting now required for all ages, previously influenza-associated mortality was reportable only in a pregnant woman or in pediatric age groups]
- Section 7(7) Hepatitis C infection in an infant or a child aged five (5) years or less [added (5) after five]

- Section 8(1) [added reporting of serum bilirubin levels and serum alanine aminotransferase levels when reporting positive hepatitis B laboratory test results or positive hepatitis C laboratory test results]
 - (c) Hepatitis B laboratory test results whether reported as positive or negative:
 - 1. Include the serum bilirubin levels taken within ten (10) days of the test of a patient who has tested positive; or
 - 2. Include the serum alanine aminotransferase levels taken within ten (10) days of the test of a patient who tested positive;
 - (d) Hepatitis C laboratory test results whether reported as positive or negative:
 - 1. Include the serum bilirubin levels taken within ten (10) days of the test of a patient who has tested positive; or
 - 2. Include the serum alanine aminotransferase levels taken within ten (10) days of the test of a patient who tested positive;
- Section 9
 - (d) Vancomycin-resistant *Enterococcus* species (VRE), only those identified to the species level, that are resistant to Vancomycin by standard susceptibility testing methods or by results from any FDA-approved test for VRE detection from specific specimen sources; [changed definition for VRE]
 - (f) Carbapenem-resistant Enterobacteriaceae (CRE), which includes *Escherichia coli*, *Klebsiella oxytoca*, *Klebsiella pneumonia*, or *Enterobacter* species testing resistant to imipenem, meropenem, doripenem, or ertapenem by standard susceptibility testing methods or by production of carbapenemase by an isolate demonstrated by using a recognized test; [changed definition for CRE]
- Section 19
 - (a) Form "EPID 200, Kentucky Reportable Disease Form", 6/2016 [revised form and publication date]
 - (c) Form "EPID 394, Kentucky Reportable Disease Form, Hepatitis Infection in Pregnant Women or Child (aged five years or less)", 9/2016; [revised form and publication date]